- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02766517
Biomarker Study in Participants With Migraine
March 29, 2019 updated by: Eli Lilly and Company
LY2951742 Biomarker Study in Patients With Migraine
This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993.
The participants received either LY2951742 or placebo.
This study NCT02766517 will evaluate how certain biomarkers may be related to the participant's response in study NCT02163993.
The study will last about five days.
Study Overview
Study Type
Interventional
Enrollment (Actual)
37
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85023
- Arizona Research Center
-
-
California
-
Encino, California, United States, 91316
- Pharmacology Research Institute, Newport Beach
-
Glendale, California, United States, 91206-4140
- Parexel Early Phase Unit at Glendale
-
Los Alamitos, California, United States, 90720
- Pharmacology Research Institute, Newport Beach
-
Newport Beach, California, United States, 92660
- Pharmacology Research Institute, Newport Beach
-
San Diego, California, United States, 92108
- Medical Center for Clinical Research
-
San Diego, California, United States, 92123
- California Clinical Trials
-
-
Florida
-
DeLand, Florida, United States, 32720
- Avail Clinical Research LLC
-
Orlando, Florida, United States, 32801
- Psychiatric Inst of Florida-Clinical Neuroscience Solutions
-
-
Maryland
-
Baltimore, Maryland, United States, 21225
- PAREXEL-Phase 1 Baltimore Harbor Hospital Center
-
Baltimore, Maryland, United States, 21208
- Pharmasite Research Inc
-
-
New York
-
Rochester, New York, United States, 14609
- Rochester Clinical Research, Inc.
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- CNS Health Care
-
-
Washington
-
Bellevue, Washington, United States, 98007-4209
- Northwest Clinical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants with migraine who have previously participated in study NTC02163993 and received one of the selected doses of galcanezumab or placebo
- Have suitable skin characteristics for the dermal capsaicin challenge
Exclusion Criteria:
- Have a history of significant allergies, in particular to ethanol or sensitivity to the fruits of capsicum plants (for example, chili peppers)
- Have eczema, scleroderma, psoriasis, dermatitis, keloids, tumors, ulcers, burns, flaps, or grafts on their forearm or other abnormality of the skin which may interfere with the study assessments
- Cannot avoid excess tanning (any exposure to sunlight or a tanning bed which would cause a sunburn reaction) throughout the study and cannot cover forearms for 24 hours prior to each treatment period
- Have excessive hair growth on the volar surface of the forearm or participants currently using lotions, oils, depilatory preparations, or other topical treatments on a regular basis which cannot be discontinued for the duration of the study; has used any topical treatments within 7 days of the start of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Capsaicin
Single topical dose of capsaicin
|
Administered topically
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Capsaicin-Induced Dermal Blood Flow (DBF)
Time Frame: Baseline (pre-capsaicin) and on assessment day over approximately one hour, after at least a 4 month wash out from treatment in study NCT02163993
|
Change from pre-capsaicin DBF adjusting for vehicle at 30 minutes is reported.
The capsaicin induced dermal blood flow (DBF) was measured by laser Doppler imaging (LDI).
|
Baseline (pre-capsaicin) and on assessment day over approximately one hour, after at least a 4 month wash out from treatment in study NCT02163993
|
Plasma Calcitonin Gene-Related Peptide (CGRP) Levels
Time Frame: On assessment day over approximately one hour, after at least a 4 month wash out from treatment in study NCT02163993
|
The mean Plasma Calcitonin Gene-Related Peptide levels were reported.
|
On assessment day over approximately one hour, after at least a 4 month wash out from treatment in study NCT02163993
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 28, 2016
Primary Completion (Actual)
January 1, 2017
Study Completion (Actual)
January 1, 2017
Study Registration Dates
First Submitted
May 6, 2016
First Submitted That Met QC Criteria
May 6, 2016
First Posted (Estimate)
May 9, 2016
Study Record Updates
Last Update Posted (Actual)
April 9, 2019
Last Update Submitted That Met QC Criteria
March 29, 2019
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16235
- I5Q-MC-S001 (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine Disorders
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
Vastra Gotaland RegionNot yet recruiting
Clinical Trials on Capsaicin
-
University of FloridaCompletedPain | FibromyalgiaUnited States
-
Nantes University HospitalRecruitingNeuropathic Pain | Coccyx Disorder | CoccygodyniaFrance
-
University of FloridaCompleted
-
NeurogesXCompletedHIV Infections | Pain | Peripheral Nervous System Diseases
-
Hospital de MataróInstituto de Salud Carlos III; Consorci Sanitari del MaresmeRecruitingStroke | Oropharyngeal Dysphagia | Swallowing Disorder | Stroke, ComplicationSpain
-
Samyang Biopharmaceuticals CorporationCompletedPostherpetic Neuralgia | Peripheral Nerve InjuryKorea, Republic of
-
Propella TherapeuticsCompletedPain | Osteoarthritis, KneeUnited States
-
The University of Texas Health Science Center,...University of California, San FranciscoActive, not recruitingMigraine | Cluster Headache | Trigeminal Autonomic Cephalgia | Hemicrania Continua | Paroxysmal Hemicrania | SUNCT | Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and TearingUnited States
-
Averitas Pharma, Inc.RecruitingPost Surgical Neuropathic PainUnited States, Spain, France, Netherlands, Poland, United Kingdom
-
Carilion ClinicChorda Pharma, Inc.Completed